Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors-Reference-Cited by-同舟云学术

Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors

Published:1998-01-28 Issue:4 Volume:41 Page:281-291
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:
Short-container-title:Cancer Chemotherapy and Pharmacology

Author:

Tranchand Brigitte,Catimel Gilles,Lucas Catherine,Sarkany Marlis,Bastian Gérard,Evene Eric,Guastalla Jean-Paul,Négrier Sylvie,Rebattu Paul,Dumortier Arlette,Foy Maurice,Grossin François,Mazier Béatrice,Froudarakis Marios,Barbet Nicolas,Clavel Michel,Ardiet Claude

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s002800050741.pdf

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impacts and Changes Related to the Cancer Drug Resistance Mechanism;Current Drug Metabolism;2024-12

2. Co (II) Complexes Based on the Bis-Pyrazol-S-Triazine Pincer Ligand: Synthesis, X-ray Structure Studies, and Cytotoxic Evaluation;Crystals;2022-05-20

3. Compound 968 reverses adriamycin resistance in breast cancer MCF-7ADR cells via inhibiting P-glycoprotein function independently of glutaminase;Cell Death Discovery;2021-08-05

4. Long non-coding RNAs in the doxorubicin resistance of cancer cells;Cancer Letters;2021-06

5. Theoretical Study of Tautomerization in 1,5-Dimethyl-6-Thioxo-1,3,5-Triazinane-2,4-Dione;Journal of Structural Chemistry;2018-05